Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis mystery: where does the phosphate come from?

NCT ID NCT03119818

Knowledge-focused Sponsor: Hospices Civils de Lyon Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study used a special MRI technique to measure phosphate and ATP (energy) levels inside muscle cells of 11 kidney dialysis patients during a 4-hour session. The goal was to find out whether phosphate removed during dialysis comes from inside cells. If it does, it might explain why some patients feel tired or unwell during treatment and could lead to changes in how dialysis is done.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If confirmed, these findings could help explain why some patients feel unwell during dialysis and may lead to better dialysis timing or methods.
What could go wrong
This is a very small, early observational study with only 11 participants. It measures chemical changes but does not test any treatment, so direct patient benefits are uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

11 people

The number who actually took part.

Started

Jun 2017

Finished

Jul 2017

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient suffering from end-stage renal disease, treated by chronic hemodialysis since at less 6 months * Phosphatemia (at the start of the session) ≥ 1,5 mmol/L and ≤ 3 mmol/L * written consent signed Exclusion Criteria: * Major subject protected by law * Prisoners or subjects who are involuntarily incarcerated * Denutrition (weight loss ≥ 5 kg in one months/10 kg in 6 months, Body Mass Index (BMI) ≤ 21 kg/m2, albuminemia ≤ 35 g/L) * Obesity (BMI ≥ 30 kg/m2) * Phosphatemia at the start of the dialysis \< 1,5 mmol/L or \> 3 mmol/L * Secondary hyperparathyroidism with parathormone (PTH) ≥ 1000 pg/mL * Adynamic osteopathy (PTH ≤ 50 pg/mL) * Hypoparathyroidism with a history of parathyroidectomy * Hemoglobin ≤ 100 g/L * Contraindication to heparin * Temporary vascular access * Contraindication to resonance magnetic spectroscopy (pacemaker or insulin pump, metallic valvular prosthesis, valvular prosthesis not compatible with resonance magnetic spectroscopy, dental appliance, intracerebral clip, claustrophobic subject). * Simultaneous participation to another research protocol * Patient not affiliated to a social security system

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for End-stage renal disease (ESRD) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

End-stage renal disease (ESRD)

Contacts and locations

Locations

  • Service de Néphrologie Pavillon P, Hôpital E. Herriot

    Lyon, 69003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.